Pfizer’s BRAFTOVI Combo Shows Longer Progression-Free Survival in First-Line BRAF V600E Metastatic Colorectal Cancer
Phase 3 BREAKWATER Cohort 3 data show encorafenib plus cetuximab with FOLFIRI extended median PFS to 15.2 months vs. 8.3 months in control.